Kodiak Sciences to present positive Phase 3 DAYBREAK eye‑drug data at AAO 2026
Kodiak Sciences announced that its Phase 3 DAYBREAK trial of Zenkuda (tarcocimab‑tedromer) and KSI‑501 met primary endpoints in wet age‑related macular degeneration. The company will showcase these results, along with Phase 3 GLOW2 data for diabetic retinopathy and Phase 1b APEX data for KSI‑101, at the American Academy of Ophthalmology meeting in early October. The data showed non‑inferior vision gains versus aflibercept and that 54% of Zenkuda‑treated patients achieved a 24‑week dosing interval at year one.
Why it matters
The company said the data keep it on track for a Biologics License Application for Zenkuda in Q4 2026, and its $125.9 million cash balance should fund operations into 2027, supporting investor optimism and a 6.4% share price rise.
Key facts
- 1Kodiak announced on October 7 that it will present data from all three late‑stage programs at AAO 2026. marketscreener.com
- 2The DAYBREAK trial met its primary endpoint for both Zenkuda and tabirafusp‑ted, showing non‑inferior vision gains versus aflibercept. marketscreener.com
- 354% of Zenkuda‑treated patients reached a 24‑week dosing interval at year one under strict retreatment criteria. quiverquant.com
- 4Kodiak ended Q2 2026 with $125.9 million in cash, sufficient to support operations into 2027. quiverquant.com
- 5Kodiak’s stock rose 6.4% on the day of the announcement. quiverquant.com
- 6The company plans a Zenkuda BLA filing in the fourth quarter of 2026. quiverquant.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.